AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00930449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Academy of Math
Description: This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide.
Study NCT01806376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutinib Maleate capsules
Description: Dose escalation will be dependent on any dose limiting toxicities
Study NCT02492685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative analysis by using the new developed software program VueBox
Description: After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
Study NCT03086161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Routine prenatal care as part of multidisciplinary adolescent pregnancy clinic, including medical (ob/gyn), nutrition, and social work
Study NCT03248947 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: buprenorphine/naloxone
Description: To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
Study NCT03248947 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacist-administered buprenorphine/naloxone maintenance care
Description: Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
Study NCT00930449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Special Education/Individualized Tutoring
Description: Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
Study NCT01105663 — intervention group
Intervention type: OTHER
Intervention: Pharmacokinetic Sampling and pharmacogenetic analysis
Description: Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
Study NCT00986310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
Study NCT00986310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
Study NCT02181010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
Study NCT02060318 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
Study NCT04460417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: The session began with the therapist reviewing the participants' personal feedback sheet within the context of clear messaging that there is no safe level of smoking and of how smoking affects the participant individually and the Black community collectively. The participant was encouraged to quit smoking, else to reduce smoking if abstinence was not desired, and to use NRT within the next week to help foster behavior change and alleviate withdrawal symptoms. This portion of the counseling was presented within a culturally-targeted framework such that myths regarding NRT common among persons with low health literacy were discussed and debunked and historical mistrust of the medical community and concerns about exploitation were also addressed. Each participant in EC was offered a starter kit of NRT with a one week supply of patches or lozenges.
Study NCT04460417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Participants met with a research assistant for 3-5 minutes and received the National Cancer Institute (NCI) pamphlet Clearing the Air and access to related online resources, which includes brief advice to quit smoking and medication information. They did not receive counseling or specialized care and were advised to refer to the resources should they be interested in quitting smoking.
Study NCT02389140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trigger point release
Description: Trigger point therapy
Study NCT02389140 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ultrasound
Description: sham ultrasound
Study NCT03843736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: 1. Balance the diet;~2. Limit high-calorie and high-fat food intake, reduce eating out, and establish regular eating habits;~3. Monitor body weight, avoid sedentary, get more sun and regular activities;~4. Mental health regulation.
Study NCT03829111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clostridium butyricum CBM 588 Probiotic Strain
Description: Given PO
Study NCT03829111 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV
Study NCT03829111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03829111 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT03843736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Agent
Description: Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
Study NCT03843736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive
Description: The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.
Study NCT03829111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT00716274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
Study NCT00716274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily, for 16 weeks
Study NCT00405288 — intervention group
Intervention type: DRUG
Intervention: Proctofoam-HC®
Description: Observational study of the exposure to Proctofoam-HC®
Study NCT02491697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK Immunotherapy
Description: DC-CIK cells are used to treat advanced breast cancer with capecitabine.
Study NCT02491697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine Monotherapy
Description: All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
Study NCT03974269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAVI : Transcatether Aortic Valve Implantation
Description: TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
Study NCT03974269 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TAVI : Transcatether Aortic Valve Implantation
Description: TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
Study NCT02194114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Diet
Description: Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
Study NCT04170920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeExtend-AI
Description: LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added.
Study NCT04042805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg intravenously every 3 weeks
Study NCT04042805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study NCT01871441 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-body irradiation
Description: Undergo TBI
Study NCT01871441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocytes infusion (DLI)
Description: Undergo DLI
Study NCT01871441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01871441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (HSCT)
Description: Undergo haploidentical allogeneic HSCT
Study NCT03822364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active comparator
Description: commercially available apomorphine injector
Study NCT03822364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 009-0
Description: Inhaled placebo via Staccato device
Study NCT03822364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-2
Description: Inhaled apomorphine via Staccato aerosol, Dose 2
Study NCT03822364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 009-3
Description: Inhaled apomorphine via Staccato aerosol, Dose 3
Study NCT03822364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-3
Description: Inhaled apomorphine via Staccato aerosol, Dose 3
Study NCT03822364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-4
Description: Inhaled apomorphine via Staccato aerosol, Dose 4
Study NCT03822364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 009-5
Description: Inhaled apomorphine via Staccato aerosol, Dose 5
Study NCT03340064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)
Study NCT00741936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MaZiRenWan (MZRW)
Description: MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
Study NCT00741936 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
Study NCT01059266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PURETHAL Grasses, 20.000 AUM/ml
Description: subcutaneous injections of increasing doses according to the described regimen
Study NCT01871441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study NCT01871441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given IV
Study NCT02579811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
Study NCT03703505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: 120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled \[14C\]AG-348.
Study NCT03703505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [13C6]AG-348
Description: IV microdose of approximately 100 micrograms (mcg), single dose.
Study NCT03846661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physiomesh
Description: difference in risk for recurrence and postoperative complication
Study NCT03571971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Load modification education
Description: Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
Study NCT03571971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise education
Description: Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
Study NCT02491697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Monotherapy
Description: All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
Study NCT04264039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 UCAR-T cells
Description: Dose range:1 to 5 ×10\^7 cells/Kg, Dose level one: 1×10\^7 cells/Kg, Dose level two: 3×10\^7 cells/Kg, Dose level three:5 ×10\^7 cells/Kg
Study NCT04264039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m\^2 per day for 6 days
Study NCT01549223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Infusion
Description: 500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
Study NCT01549223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin Bolus
Description: 3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
Study NCT03641547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620
Description: M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre-clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
Study NCT03641547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 \& B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
Study NCT03641547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre-cursor of the cytotoxic 5-fluourouracil. Capecitabine use is not considered standard practice in Stage A2 \& B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
Study NCT03641547 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
Study NCT04264039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 300mg/m\^2 per day for 2 to 6 days determined by tumor burden at baseline
Study NCT04264039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 50 to 70 mg/m\^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
Study NCT01398267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily, 4 weeks (Day 15 to Day 43)
Study NCT04168931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: The first-line standard treatment for gastric cancer is based on fluoropyrimidine and platinum-containing chemotherapy (FOLFOX). When the tumor expresses HER2 3+ on IHC or 2+ and is confirmed by FISH, trastuzumab at the standard dose of 8 mg / kg in D1 of the first cycle is added, followed by 6 mg / kg every 2 weeks for the remaining cycles until disease progression, unacceptable toxicity. (3) We will use the same doses of trastuzumab, but HER2 positivity is determined by immunocytochemical expression and FISH in CTCs for patients with negative expression in tissue biopsy.
Study NCT01398267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: 20 mg orally daily, 6 weeks (Day 1 to Day 43)
Study NCT01398267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lisinopril
Description: 20 mg orally daily, 6 weeks (Day 1 to Day 43)
Study NCT01398267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
Study NCT03411772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: Injection of 20 mL of 0.25% bupivacaine in the transversus abdominis plane under ultrasound guidance after performing bariatric surgery
Study NCT03411772 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery will be conducted
Study NCT01041612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTFE Covered ComVi [full covered] Biliary Stent
Description: The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
Study NCT00422006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy of muscle, of liver, and of adipose tissue
Description: biopsy of muscle, of liver, and of adipose tissue
Study NCT01991379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
Study NCT01991379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
Study NCT03411772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery will be conducted
Study NCT01991379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws